Key result
CTRP3 shows potential as a cardiovascular therapeutic target by regulating metabolism and inhibiting inflammation.
Why the study?
CTRP3 plays important roles in glucose/lipid metabolism, inflammation, and cardiovascular protection, but its implications in obesity, metabolic dysfunction, and cardiovascular diseases require comprehensive synthesis.
This review highlights the potential of CTRP3 as a therapeutic target for obesity, metabolic dysfunction, and cardiovascular diseases due to its role in metabolism and inflammation.
CTRP3 merits exploration as a cardiometabolic therapeutic target; leaves open clinical adoption pending interventional trials.
Adipose tissue, as the largest endocrine organ, secretes many biologically active molecules circulating in the bloodstream, collectively termed adipocytokines, which not only regulate the metabolism but also play a role in pathophysiological processes. C1q tumor necrosis factor (TNF)-related protein 3 (CTRP3) is a member of C1q tumor necrosis factor-related proteins (CTRPs), which is a paralog of adiponectin. CTRP3 has a wide range of effects on glucose/lipid metabolism, inflammation, and contributes to cardiovascular protection. In this review, we comprehensively discussed the latest research on CTRP3 in obesity, diabetes, metabolic syndrome, and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2020) conducted a review in Obesity, Metabolic Dysfunction, and Cardiovascular Diseases. CTRP3 was evaluated. CTRP3 is a novel adipokine that regulates glucose and lipid metabolism, inhibits inflammation, and provides cardiovascular protection, highlighting its potential as a therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: